Evidence map›Paper›PMID 28992413›Full record

ArticleJournal of medicinal chemistry2018

Phenotypic Optimization of Urea-Thiophene Carboxamides To Yield Potent, Well Tolerated, and Orally Active Protective Agents against Aminoglycoside-Induced Hearing Loss.

Sarwat Chowdhury, Kelly N Owens, R Jason Herr, Qin Jiang, Xinchao Chen, Graham Johnson, Vincent E Groppi, David W Raible, Edwin W Rubel, Julian A Simon

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05730283 (Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Non-Tuberculous Mycobacterium Disease), which is not on this map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05730283 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Non-Tuberculous Mycobacterium Disease

TypeinterventionalSponsorKevin WinthropRan2025 to 2028Enrolled105ConditionsOtotoxicity, Drug-InducedArmsORC-13661, Placebo
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Tropanes in natural products, syntheses, and drugs: some insights from the new millennium.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  4. Article
  5. Review
  6. Pharmacological Approaches to Hearing Loss.Pharmacological reviews · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. AnFrontiers in molecular neuroscience · 2022
    Article
  16. Hair cell toxicology: With the help of a little fish.Frontiers in cell and developmental biology · 2022
    Review
  17. Article
  18. Mechanisms of Ototoxicity and Otoprotection.Otolaryngologic clinics of North America · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sarwat Chowdhury
Kelly N OwensVirginia Merrill Bloedel Hearing Research Center, University of Washington , Seattle, Washington 98195, United States.
R Jason HerrAMRI , Albany, New York 12203, United States.
Qin JiangAMRI , Albany, New York 12203, United States.
Xinchao ChenAMRI , Albany, New York 12203, United States.
Graham JohnsonNuPharmAdvise LLC , Sanbornton, New Hampshire 03269 United States.
Vincent E GroppiCenter for Discovery of New Molecules, University of Michigan , Ann Arbor, Michigan 48109, United States.
David W RaibleVirginia Merrill Bloedel Hearing Research Center, University of Washington , Seattle, Washington 98195, United States.
Edwin W RubelVirginia Merrill Bloedel Hearing Research Center, University of Washington , Seattle, Washington 98195, United States.
Albany Molecular Research (United States) · USUniversity of Washington · USOricula Therapeutics (United States) · USUniversity of Michigan · US

Funding

Genetics of Zebrafish Hair Cell ToxicityR01DC005987 · NIDCD · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 2003 to 2023
$9.8M
Chemoprotection Against Aminoglycoside-Induced OtotoxicityR01DC009807 · NIDCD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SIMON, JULIAN · 2009 to 2013
$2.0M
Drug Discovery for the Prevention of Hearing LossU01NS074506 · NINDS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W, RUBEL, EDWIN W · 2011 to 2012
$516k
Drug Discovery for the Prevention of Hearing LossR01DC013688 · NIDCD · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W, RUBEL, EDWIN W · 2013 to 2015
$296k
NIDCD NIH HHS R01 DC005987NIDCD NIH HHS R01 DC009807NIDCD NIH HHS R01 DC013688NINDS NIH HHS U01 NS074506
6 · The paper itself

Abstract

Hearing loss is a major public health concern with no pharmaceutical intervention for hearing protection or restoration. Using zebrafish neuromast hair cells, a robust model for mammalian auditory and vestibular hair cells, we identified a urea-thiophene carboxamide, 1 (ORC-001), as protective against aminoglycoside antibiotic (AGA)-induced hair cell death. The 50% protection (HC

Indexed as

SafetyAdministration, OralAminoglycosidesAnimalsDrug Evaluation, PreclinicalHearing LossRatsStructure-Activity RelationshipThiophenesUreaZebrafishAminoglycosidesThiophenesUrea

Identifiers

PMID28992413
PMCPMC5889090
OpenAlexW2764007778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.